Welcome to our dedicated page for Oncotelic Therapeutics SEC filings (Ticker: OTLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncotelic Therapeutics, Inc. (OTLC) SEC filings page on Stock Titan provides direct access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q, S-1, S-1/A, 8-K, and related documents. As a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and rare pediatric indications, Oncotelic uses these filings to report on its financial condition, capital-raising activities, joint ventures, and material agreements.
Recent Form 8-K filings detail unregistered sales of equity securities through unit offerings of notes and warrants to accredited investors, including conversion features into Oncotelic common stock or shares of consolidated minority-owned subsidiary EdgePoint AI, Inc. They also describe amendments to independent contractor and restricted stock agreements tied to market capitalization milestones, as well as corporate presentations and press releases, such as the announcement of open access to the PDAOAI platform and its TGF-β literature corpus.
Registration statements on Form S-1 and Form S-1/A outline resale arrangements with Mast Hill Fund, LP under a Note Purchase Agreement and an Equity Purchase Agreement. These documents specify the number of shares registered, warrant coverage, and the company’s status as a smaller reporting company. Together with periodic reports, they give investors insight into equity structures, potential dilution, and ongoing financing strategies.
Additional filings, such as Form 12b-25 (NT 10-Q), explain timing extensions for quarterly reports and provide context on anticipated changes in results of operations. By reviewing these filings, users can understand how Oncotelic structures its financings, manages joint venture interests like GMP Bio and Sapu Nano, and discloses risks and forward-looking statements associated with its oncology, RNA therapeutic, nanomedicine, and AI-driven platforms. Stock Titan’s interface, combined with AI-powered summaries, helps interpret complex disclosures, highlight key terms in offerings and agreements, and surface material events that may be relevant to OTLC shareholders and analysts.
Oncotelic Therapeutics, Inc. filed an amended registration statement covering the resale of 115,600,000 shares of common stock by Mast Hill Fund, LP. These shares include up to 100,000,000 shares issuable under an equity purchase agreement, 8,000,000 shares from note conversion, 5,350,000 warrant shares and 2,250,000 commitment fee shares, plus additional shares for potential stock adjustments. If all are issued and sold, they would represent 20.1% of the company’s common stock as calculated in the prospectus. Oncotelic will not receive proceeds from Mast Hill’s market sales, but will receive cash when it issues shares to Mast Hill under put notices. The company is a clinical-stage oncology and AI-focused biotech with a minority interest in JV GMP Bio, limited cash of $409,000 versus current liabilities of $20.1 million, and a nine‑month 2025 net loss attributable to Oncotelic of $1.07 million, and its auditor has raised substantial doubt about its ability to continue as a going concern.
Oncotelic Therapeutics, Inc. entered into subscription agreements with accredited investors for 11 units in a private Offering of notes and warrants. Each unit includes a note with $25,000 principal, bearing 12% annual interest and maturing two years after the final closing of the Offering, plus warrants tied to Oncotelic or EdgePoint AI, Inc. shares at fixed conversion and exercise prices, subject to anti-dilution adjustments.
Investors in the company’s 2023 PPM notes can exchange their old notes for these new units, with prior warrants extended by two years and an option to convert EdgePoint shares into Oncotelic common stock at $0.10 per share. The company also granted registration rights for the Oncotelic shares underlying the notes and warrants. The securities were issued as unregistered securities under Section 4(a)(2) and Rule 506 of Regulation D.
Oncotelic Therapeutics, Inc. has filed a Form S-1 covering the resale of 309,717,647 shares of common stock by Mast Hill Fund, LP. The shares include up to 294,117,647 shares issuable under an Equity Purchase Agreement, 10,000,000 shares from conversion of debt under a Note Purchase Agreement and related warrants, plus 2,250,000 commitment fee shares and customary anti-dilution adjustments.
The company will not receive any proceeds from Mast Hill’s resale of these shares, but will receive cash when it issues shares to Mast Hill under put notices in the Equity Purchase Agreement. As of November 17, 2025, the shares that may be sold would represent about 39.1% of the company’s common stock, assuming full issuance, conversion and warrant exercise under these arrangements.
Oncotelic is a clinical-stage biopharma company focused on orphan oncology and other indications through its own pipeline and a joint venture, with its principal asset a minority interest in GMP Bio. The company has no product revenue, reported an accumulated deficit of about $39.1 million and a net loss attributable to Oncotelic of about $1.1 million for the nine months ended September 30, 2025, and its auditors express substantial doubt about its ability to continue as a going concern.
Oncotelic Therapeutics, Inc. (OTLC) disclosed an insider equity award for Chairman and CEO Vuong Trieu, who is also a director and 10% owner. A Form 4 reports that he received 4,065 shares of Series A Convertible Preferred Stock on 11/17/2025, classified as an acquisition. Each preferred share is convertible at the holder’s option into common stock on a one-for-one thousand basis, representing 4,065,000 underlying common shares. The preferred shares were issued to Dr. Trieu as compensation tied to performance milestones under a Restricted Stock Agreement dated November 17, 2025, and are held directly.
Oncotelic Therapeutics, Inc. reported no revenue for the three and nine months ended September 30, 2025 and continued to operate at a loss. Net loss attributable to the company was $1.05 million for the quarter, improving from $3.30 million a year earlier, and $1.07 million for the nine‑month period versus $3.92 million in 2024. Operating expenses fell sharply year over year due to the absence of a prior $3.2 million goodwill impairment.
Cash and restricted cash totaled $429,000 at September 30, 2025, while current liabilities were $20.1 million, including $10.3 million of convertible and short‑term debt and $3.5 million of related‑party debt. Management discloses a substantial doubt about the company’s ability to continue as a going concern, citing cumulative losses of about $39.1 million, negative working capital of roughly $18.5 million, and negative operating cash flow. The company is relying on convertible notes, short‑term related‑party loans, and equity purchase agreements with Peak One and Mast Hill, while its 45% stake in JV partner GMP Bio is carried at $22.65 million based on a Level 3 fair value election.
Oncotelic Therapeutics, Inc. filed a Form 12b-25, notifying a late Form 10-Q for the quarter ended September 30, 2025.
The company says it was unable to compile the necessary financial information to complete the filing without unreasonable effort or expense and expects to file within the permitted extension period. The notification lists Amit Shah, Chief Financial Officer, as the signatory and contact.
Oncotelic Therapeutics (OTLC) furnished an investor presentation given by CEO Dr. Vuong Trieu at LD Micro in San Diego on October 21, 2025. The presentation, filed as Exhibit 99.1, includes forward-looking statements covering areas such as JV plans (including a potential IPO), clinical development timing and data reporting, regulatory approvals, the company’s nanoparticle platform, a planned DAO-based company, pet and animal health initiatives, and token-related registrations and tradability.
The materials are furnished under Item 8.01 and are not deemed “filed,” which limits their incorporation into other SEC filings.